Ubs Group Ag Silence Therapeutics PLC Transaction History
Ubs Group Ag
- $611 Billion
- Q3 2025
A detailed history of Ubs Group Ag transactions in Silence Therapeutics PLC stock. As of the latest transaction made, Ubs Group Ag holds 307,363 shares of SLN stock, worth $2.11 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
307,363
Previous 228,509
34.51%
Holding current value
$2.11 Million
Previous $1.33 Million
20.38%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding SLN
# of Institutions
54Shares Held
20.6MCall Options Held
0Put Options Held
0-
Tcg Crossover Management, LLC Palo Alto, CA3.03MShares$20.8 Million1.76% of portfolio
-
Siren, L.L.C. New York, NY2.91MShares$20 Million0.59% of portfolio
-
Redmile Group, LLC San Francisco, CA2.16MShares$14.9 Million1.24% of portfolio
-
Lombard Odier Asset Management (Usa) Corp New York, NY1.84MShares$12.7 Million0.69% of portfolio
-
Morgan Stanley New York, NY1.21MShares$8.3 Million0.0% of portfolio
About Silence Therapeutics plc
- Ticker SLN
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 35,888,400
- Market Cap $247M
- Description
- Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated...